Compositions for treating neurodegenerative diseases
The present disclosure relates to novel compounds, and pharmaceutical compositions thereof, useful for treating for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed. Representative members of these compounds include:
1. A compound of Formula I or pharmaceutically acceptable salt thereof:
wherein:
each of R a , R b , R c , R d and R e is independently selected from the group consisting of, H, hydroxyl, halo, alkyl, alkoxy, CF 3 , SO 2 CH 3 , and morpholino;
R 1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH═C(CH 3 ) 2 ; and
R 2 is an optionally substituted cyclic amino group;
selected from the groups consisting of:
2. The compound of claim 1 , selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
4. The pharmaceutical composition of claim 3 wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
5. A method of treating Alzheimer's disease comprising administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition according to claim 3 .
6. A method for inhibiting cognitive decline in a subject exhibiting, or at risk of exhibiting, cognitive decline, comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 3 .
7. A method of inhibiting amyloid beta effect on a neuronal cell comprising administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition according to claim 3 .
8. A method of treating mild cognitive impairment in Alzheimer's disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 3 .